Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasi...
- Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp’s psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal.
In March, the FTC had sought additional information from the companies as it focused on their psoriasis treatments as part of its review of their planned merger. “The company is continuing to develop its promising immunology pipeline asset, tyrosine kinase 2 inhibitor, in several autoimmune diseases, including psoriasis,” Bristol said in a statement.
Bristol said it remains actively engaged in discussions with the FTC on continued review of its offer to buy Celgene.
Brasil Últimas Notícias, Brasil Manchetes
Similar News:Você também pode ler notícias semelhantes a esta que coletamos de outras fontes de notícias.
Bristol to divest Celgene's psoriasis treatment in FTC clearance pushBristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psori...
Consulte Mais informação »
Bristol to divest Celgene's psoriasis treatment in FTC clearance pushBristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psori...
Consulte Mais informação »
Dementia risk tied to these commonly prescribed drugs, study saysThere was nearly a 50% increased odds of dementia among adults aged 55 and older in the United Kingdom who took a strong anticholinergic medication daily for at least three years, according to a new study.
Consulte Mais informação »
Vyleesi: New drug for women with low sex drive gets FDA approvalThe FDA has approved a new medication that will boost libido in women with low sexual desire, so that they too can have an enjoyable sex life.
Consulte Mais informação »
'Michael Jackson drug' still prompts curiosity from patientsIt remains the most widely used anesthetic in U.S. hospitals, but many patients still remember propofol as the drug that killed Michael Jackson.
Consulte Mais informação »